A61K 2039/80
Vaccine for a specifically defined cancer
Official title: {Vaccine for a specifically defined cancer}
A61K2039/80 (Vaccine for a specifically defined cancer) appears on 701 US grants and 1,653 published applications in this corpus.
Search patents in A61K- Granted patents
- 701
- Published applications
- 1,653
- Assignees
- 711
- Inventors
- 3,173
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 9 |
| 2003 | 0 | 6 |
| 2004 | 1 | 12 |
| 2005 | 1 | 7 |
| 2006 | 0 | 15 |
| 2007 | 2 | 5 |
| 2008 | 4 | 15 |
| 2009 | 2 | 16 |
| 2010 | 4 | 22 |
| 2011 | 7 | 22 |
| 2012 | 6 | 14 |
| 2013 | 12 | 25 |
| 2014 | 16 | 25 |
| 2015 | 12 | 26 |
| 2016 | 16 | 31 |
| 2017 | 14 | 28 |
| 2018 | 26 | 52 |
| 2019 | 40 | 117 |
| 2020 | 51 | 149 |
| 2021 | 69 | 234 |
| 2022 | 78 | 250 |
| 2023 | 81 | 177 |
| 2024 | 85 | 169 |
| 2025 | 102 | 137 |
| 2026 | 60 | 90 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- A61K 2039/804Blood cells [leukemia, lymphoma]Indexing code168
- A61K 2039/812BreastIndexing code109
- A61K 2039/876Skin, melanomaIndexing code107
- A61K 2039/892Reproductive system [uterus, ovaries, cervix, testes]Indexing code101
- A61K 2039/86LungIndexing code75
- A61K 2039/884ProstateIndexing code73
- A61K 2039/82ColonIndexing code60
- A61K 2039/852PancreasIndexing code55
Recent patents
- Cancer vaccine22 Sep 2026US 12,741,017 B2Cancer Research Malaysia
- Oncolytic virus in combination with immune checkpoint inhibitor for treating tumors15 Sep 2026US 12,734,202 B2Joint Biosciences (Sh) Ltd.
- Fusion peptide vaccines15 Sep 2026US 12,734,225 B2Treos Bio Limited
- Intracellular delivery of biomolecules to modify immune response8 Sep 2026US 12,728,163 B2Stemcell Technologies Canada Inc.
- Compositions and methods for cancer therapy25 Aug 2026US 12,714,723 B2AIM ImmunoTech Inc.
- Sarcoma cancer vaccines and uses thereof8 Oct 2026US 2026/0306600 A1
- A novel non-stoichiometric multi-element adjuvant (nsma) and composition thereof8 Oct 2026US 2026/0306624 A1Magvitae Innovations Inc
- Peptide-based vaccines and methods for treatment24 Sep 2026US 2026/0284163 A1The Johns Hopkins University
- Compositions and methods for treatment or prventative treatment of cancer including triple negative breast cancer and/or lung cancer24 Sep 2026US 2026/0284165 A1The Medical College of Wisconsin, Inc.
- Combination therapy to treat brain cancer17 Sep 2026US 2026/0273035 A1Inovio Pharmaceuticals, Inc.
Most cited
By later US patents
- Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer84US 7,919,467 B2Immunotope, Inc. · 2011
- Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor59US 5,478,556 A1995
- Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene58US 9,889,160 B2Precision BioSciences, Inc. · 2018
- Methods for reducing global chronic inflammation and the presence of melanoma51US 9,387,244 B2Mayo Foundation for Medical Education and Research · 2016
- Method for treating cancer with an antibody to CD223 protein43US 9,005,629 B2St. Jude Children?S Research Hospital · 2015